Exploring the potential of IL-10 for risk assessment and early intervention in pediatric ALL

BMC Cancer. 2024 Aug 8;24(1):972. doi: 10.1186/s12885-024-12677-w.

Abstract

Acute lymphoblastic leukemia (ALL), a leading cause of childhood cancer, targets immune system B and T cells. While understanding its causes is crucial, predicting susceptibility holds immense power for early diagnosis and intervention. This study explored the potential of interleukin 10 (IL-10), a key immune regulator, as a predictive tool in Egyptian children. Investigating 100 ALL patients and 100 healthy controls, we analyzed the IL10 gene polymorphism (-1082 A/G) and serum levels. Strikingly, both the G allele and higher serum IL-10 levels were significantly associated with increased ALL risk (p < 0.05, OR > 1). Moreover, IL-10 emerged as a remarkably accurate predictor, boasting an AUC of 0.995, with a sensitivity of 97% and specificity of 96%. These findings unveil the potential of IL-10 as a powerful predictive tool for pediatric ALL in the studied Egyptian population. Identifying individuals with the GG/AG haplotype and elevated IL-10 levels could enable early intervention and potentially improve outcomes. While further validation in larger and more diverse populations is needed, this study paves the way for personalized risk assessment and potentially revolutionizes how we combat this childhood killer.

Keywords: ALL; Cytokine levels; Gene polymorphism; IL10.

MeSH terms

  • Adolescent
  • Alleles
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / genetics
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Egypt / epidemiology
  • Female
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Infant
  • Interleukin-10* / blood
  • Interleukin-10* / genetics
  • Male
  • Polymorphism, Single Nucleotide
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / blood
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Risk Assessment / methods

Substances

  • Interleukin-10
  • IL10 protein, human
  • Biomarkers, Tumor